Fragments: where are we now?

Area of Science:

• Medicinal Chemistry
• Drug Discovery and Development
• Biotechnology

Background:

• Fragment-based drug discovery (FBDD) is a widely adopted strategy for identifying novel chemical matter in drug development.
• Four drugs approved by regulatory bodies and over forty compounds in clinical trials originate from FBDD approaches.
• Significant challenges exist in FBDD, including library design and the detection of low-affinity compounds.

Purpose of the Study:

• To provide a comprehensive overview of the current advancements in fragment-based drug discovery.
• To discuss progress in fragment library design, fragment-to-lead optimization, and screening methodologies.
• To highlight future opportunities and persistent challenges within the FBDD field.

Main Methods:

• Review of current literature and industry practices in fragment library design.
• Analysis of established and emerging techniques for fragment screening and hit identification.
• Evaluation of strategies for optimizing fragment hits into lead compounds.

Main Results:

• Fragment-based drug discovery has demonstrated significant success, leading to multiple approved drugs and numerous clinical candidates.
• Ongoing innovations in library design and screening technologies are enhancing the efficiency of FBDD.
• Fragment-to-lead optimization remains a critical area for development.

Conclusions:

• FBDD is a validated and powerful approach in modern drug discovery.
• Continued advancements in methodologies are crucial for overcoming existing challenges.
• The field presents substantial future opportunities for the development of novel therapeutics.